AstraZeneca: agreement with Takeda for Parkinson's disease.
(CercleFinance.com) - AstraZeneca has entered into an agreement with Japan's Takeda to jointly develop and market a potential treatment for Parkinson's disease.
Under the terms of the agreement, AstraZeneca will lead Phase I development of antibody MEDI1341, while Takeda will lead future clinical development activities.
The companies will then equally share future development and marketing costs for the compound, as well as any future revenues.
Takeda will pay AstraZeneca up to 400 millio dollars, including initial revenue in 2017 and development and sales milestone payments thereafter.
AstraZeneca said it has chosen Takeda because of its excellent track record in neuroscience research.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Under the terms of the agreement, AstraZeneca will lead Phase I development of antibody MEDI1341, while Takeda will lead future clinical development activities.
The companies will then equally share future development and marketing costs for the compound, as well as any future revenues.
Takeda will pay AstraZeneca up to 400 millio dollars, including initial revenue in 2017 and development and sales milestone payments thereafter.
AstraZeneca said it has chosen Takeda because of its excellent track record in neuroscience research.
Copyright (c) 2017 CercleFinance.com. All rights reserved.